Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Read More
In a major relief to paediatric Non-Alcoholic Fatty Liver Disease (NAFLD) patients, a new blood test could become clinical practice within five years, reducing the need for a liver biopsy in the patients. ...
